Letrofar

Letrozole, the active ingredient in Letrofar, is an aromatase inhibitor presented as an oral tablet for oral use. It treats postmenopausal estrogen receptor‑positive breast cancer by lowering estrogen levels that fuel tumor growth. The drug complies with EU pharmaceutical standards and is supplied in a quality‑controlled formulation.

GNH USA supplies Letrofar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozole is an aromatase inhibitor used in the endocrine treatment of hormone‑dependent breast cancer.

Postmenopausal estrogen receptor‑positive breast cancer: reduces risk of disease recurrence and progression. Advanced/metastatic breast cancer in postmenopausal women: slows tumor growth and extends survival. Adjuvant therapy after surgery in hormone‑responsive breast cancer: helps prevent cancer return. Neoadjuvant treatment of locally advanced breast cancer: may shrink tumor before surgery.

Letrozole may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint and muscle pain: arthralgia or myalgia. - Fatigue: persistent tiredness. - Nausea: upset stomach.

Serious or Rare Side Effects: - Severe liver injury: jaundice or markedly elevated enzymes. - Bone fractures: increased risk due to reduced bone mineral density. - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Allergic reactions: rash, swelling, or anaphylaxis.

When prescribing Letrofar, clinicians should consider several safety measures.

Monitor bone health: assess calcium and vitamin D status regularly. Assess cardiovascular risk: review history of heart disease or thrombotic disorders. Check liver function: obtain baseline hepatic enzyme measurements. Avoid use in premenopausal women: drug is not indicated for this population. Pregnancy and lactation: contraindicated due to unknown safety. Store at ambient temperature below 25°C: keep in the original container, protect from moisture.

Letrofar can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent estrogen replacement therapy: diminishes Letrofar efficacy. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower plasma concentrations. - Tamoxifen: antagonistic effect on estrogen pathways. - Warfarin: potential increase in anticoagulant effect.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors: possible additive bone‑loss risk. - Statins: monitor lipid profile for changes. - Certain antidepressants (e.g., venlafaxine): may exacerbate hot flashes.